W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
Conditions
Interventions
- DRUG: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Sponsor
Stiefel, a GSK Company
Collaborators